Dalcetrapib is under clinical development by DalCor Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dalcetrapib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dalcetrapib overview
Dalcetrapib is under development for the treatment of acute coronary syndrome and Coronavirus disease 2019 (COVID-19). Dalcetrapib acts by targeting cholesteryl ester transfer protein (CETP). Dalcetrapib increases the levels of high-density lipoprotein cholesterol (HDLC) thereby potentially reducing the risk of cardiovascular disease and death in high-risk patients. It is administered through the oral route. It was under development for the treatment of dyslipidemia, atherosclerosis, risk reduction in coronary heart disease/cardiovascular disease, and hyperlipidemia.
DalCor Pharmaceuticals overview
DalCor Pharmaceuticals researches and develops precision medicine for patients suffering from cardiovascular diseases. The company is engaged in the development of Dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor that is intended to reduce cardiovascular events in a genetically distinct subset of patients. DalCor Pharmaceuticals also develops dal- GenE which is used for the treatment of cardiovascular diseases, myocardial infarction (heart attack) and stroke. It holds the license to develop, manufacture and commercialise dalcetrapib, and holds the right to the genetic marker for use with dalcetrapib in patients with the ADCY9 AA genotype. The company operates in Canada, the US, Switzerland and the UK. DalCor Pharmaceuticals is headquartered in Montreal, Quebec, Canada.
For a complete picture of Dalcetrapib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
